 | |
| Company type | Public (Société Anonyme) |
|---|---|
| Euronext Paris: ABVX | |
| ISIN | FR0012333284 |
| Industry | |
| Founded | 4 December 2013 |
| Founder | Phillipe Pouletty |
| Headquarters | , |
Key people | Marc de Garidel (CEO) |
Number of employees | 27 |
| Website | www |
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has one program in clinical development with its lead drug candidate, obefazimod (formerly ABX464), to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, MA. Abivax’s R&D work is conducted at its research center based in Montpellier, France.